ATE412684T1 - Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen - Google Patents

Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen

Info

Publication number
ATE412684T1
ATE412684T1 AT03752256T AT03752256T ATE412684T1 AT E412684 T1 ATE412684 T1 AT E412684T1 AT 03752256 T AT03752256 T AT 03752256T AT 03752256 T AT03752256 T AT 03752256T AT E412684 T1 ATE412684 T1 AT E412684T1
Authority
AT
Austria
Prior art keywords
soluble polymer
carboxyl groups
polymer derivatives
terminal carboxyl
producing water
Prior art date
Application number
AT03752256T
Other languages
English (en)
Inventor
Antoni Kozlowski
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Application granted granted Critical
Publication of ATE412684T1 publication Critical patent/ATE412684T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/002Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from unsaturated compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33317Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/38Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group
    • C08G2650/42Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group containing orthoester groups
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
AT03752256T 2002-09-09 2003-09-09 Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen ATE412684T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40934802P 2002-09-09 2002-09-09

Publications (1)

Publication Number Publication Date
ATE412684T1 true ATE412684T1 (de) 2008-11-15

Family

ID=31978747

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03752256T ATE412684T1 (de) 2002-09-09 2003-09-09 Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen

Country Status (11)

Country Link
US (5) US7569214B2 (de)
EP (1) EP1537163B1 (de)
JP (1) JP4959133B2 (de)
KR (1) KR100967334B1 (de)
AT (1) ATE412684T1 (de)
AU (1) AU2003270555B2 (de)
CA (1) CA2497980C (de)
DE (1) DE60324435D1 (de)
ES (1) ES2315526T3 (de)
MX (1) MXPA05002632A (de)
WO (1) WO2004022629A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
ATE412684T1 (de) * 2002-09-09 2008-11-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
ATE460451T1 (de) * 2003-07-22 2010-03-15 Nektar Therapeutics Verfahren zur herstellung von funktionalisierten polymeren aus polymeralkoholen
US7612153B2 (en) * 2004-10-25 2009-11-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) and uses thereof
US8568705B2 (en) * 2005-07-18 2013-10-29 Nektar Therapeutics Method for preparing branched functionalized polymers using branched polyol cores
EP2364735A3 (de) 2005-12-16 2012-04-11 Nektar Therapeutics Verzweigte PEG-Kon jugate von GLP-1
CA2650035C (en) 2006-04-27 2015-02-03 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
US20100196516A1 (en) * 2007-04-24 2010-08-05 ALFAMA-Investigacao e Desenvolvimento de produtos Farmaceuticos, Lda Treatment of infections by carbon monoxide
EP2166981B1 (de) 2007-06-21 2016-09-07 Tyrx, Inc. Phenylester-seitenketten zur erhöhung der polymerresorbierbarkeit
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (de) 2010-10-01 2018-06-27 ModernaTX, Inc. Manipulierte nukleinsäuren und anwendungsverfahren dafür
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2699242B1 (de) 2011-04-19 2017-11-01 Alfama, Inc. Kohlenmonoxidfreisetzende moleküle und ihre verwendungen
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドAlfama,Inc. 一酸化ルテニウム放出分子およびその使用
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
JP6693096B2 (ja) * 2015-11-20 2020-05-13 日油株式会社 末端カルボキシ基を有するポリエチレングリコールの製造方法
US10342797B2 (en) * 2016-03-13 2019-07-09 LivePet, LLC Solubility of therapeutic agents
JP6935059B2 (ja) 2017-03-30 2021-09-15 日油株式会社 カルボキシル基を一つ有するポリエチレングリコールの精製方法
WO2020203583A1 (ja) * 2019-03-29 2020-10-08 日油株式会社 末端カルボキシル基含有ポリエチレングリコールの製造方法および活性化ポリエチレングリコールの製造方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
DE2631656C2 (de) * 1976-07-14 1983-02-10 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung eines Hydroxysuccinimidoester-Derivats zur Bindung von biologisch aktiven Proteinen aneinander und/oder an flüssige oder feste Trägerstoffe
EP0206448B1 (de) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4943626A (en) * 1988-07-29 1990-07-24 The Dow Chemical Company Primary polyether active hydrogen compounds which are prepared from linked, protectively initiated polyalkyleneoxides
US4957998A (en) * 1988-08-22 1990-09-18 Pharmaceutical Delivery Systems, Inc. Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5157075A (en) * 1990-05-02 1992-10-20 Taenaka Mining Co., Ltd. Modified melanin
US5483008A (en) * 1992-02-07 1996-01-09 Research Development Corporation Of Japan Polyether having heterofunctional groups at both ends, process for the preparation thereof and polymerization initiator therefor
JP3236087B2 (ja) * 1992-10-26 2001-12-04 株式会社トクヤマ 重合性磁性流体製造用界面活性剤
US5256819A (en) * 1992-12-24 1993-10-26 Shell Oil Company Preparation of polyoxyalkylene-alpha,omega-dicarboxylic acids
DE4314627A1 (de) * 1993-05-04 1994-11-10 Bayer Ag Verfahren zur Herstellung von Ethercarbonsäuren
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5634971A (en) * 1995-10-25 1997-06-03 Petrolite Corporation Process for dispersing pigments with polyoxyalkylated ethers
KR100441821B1 (ko) 1996-03-05 2004-10-15 구르뉘 로베르 완충화된오르토에스테르중합체를함유하는약학조성물
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US5763538A (en) * 1996-10-28 1998-06-09 E. I. Du Pont De Nemours And Company Process for making an oriented polyester article having improved hydrolytic stability
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
SE513181C2 (sv) 1997-12-19 2000-07-24 Akzo Nobel Nv En ortoesterbaserad tensid, dess tillverkning och användning
US5939453A (en) 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
EP1446438A2 (de) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Verzweigte polymere und ihre konjugate
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
ATE344289T1 (de) 2002-07-24 2006-11-15 Hoffmann La Roche Polyethylenglykol-aldehydderivate
ATE412684T1 (de) * 2002-09-09 2008-11-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen

Also Published As

Publication number Publication date
AU2003270555B2 (en) 2009-01-29
US8182801B2 (en) 2012-05-22
US20090264600A1 (en) 2009-10-22
US8435504B2 (en) 2013-05-07
US20120209027A1 (en) 2012-08-16
DE60324435D1 (de) 2008-12-11
JP2005538226A (ja) 2005-12-15
US7569214B2 (en) 2009-08-04
US20140296541A1 (en) 2014-10-02
KR100967334B1 (ko) 2010-07-05
EP1537163A2 (de) 2005-06-08
US20130231490A1 (en) 2013-09-05
CA2497980C (en) 2011-06-21
WO2004022629A3 (en) 2004-04-08
KR20050057276A (ko) 2005-06-16
US20050036978A1 (en) 2005-02-17
WO2004022629A2 (en) 2004-03-18
ES2315526T3 (es) 2009-04-01
US8784791B2 (en) 2014-07-22
JP4959133B2 (ja) 2012-06-20
EP1537163B1 (de) 2008-10-29
MXPA05002632A (es) 2005-09-20
US9045494B2 (en) 2015-06-02
CA2497980A1 (en) 2004-03-18
AU2003270555A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
ATE412684T1 (de) Verfahren zur herstellung von wasserlöslichen polymerderivaten mit terminalen carboxylgruppen
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
EP1378828A3 (de) Verfahren und System zur Verknüpfung von Eigenschaften mit Objekten
ATE410791T1 (de) Verfahren zur dotierung von polymeren
ATE382652T1 (de) Verfahren zur herstellung von polyamidblends mit hohem weichmachergehalt
ATE331804T1 (de) Verfahren zur herstellung von ansamitocin
ATE434001T1 (de) Verfahren zur herstellung wässriger polymerdispersionen
ATE553210T1 (de) Verfahren zur herstellung von l-threonin unter verwendung eines mikroorganismus mit inaktivierten galr gen.
ATE537173T1 (de) Verfahren zur herstellung von cucurbiturilen
ATE366710T1 (de) Verfahren zur herstellung von molekularsieben
ATE461960T1 (de) Verfahren zur herstellung von polymermaleimiden
ATE289703T1 (de) Verfahren zur herstellung von pi-konjugierten polymeren
ATE384754T1 (de) Verfahren zur herstellung von hochverzweigten polyamiden
DE60105314D1 (de) Verfahren zur herstellung von taxanderivaten
DE502005001316D1 (de) Verfahren zur herstellung von gut in wasser redispergierbaren polymerisatpulvern
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
ATE391115T1 (de) Verfahren zur herstellung von diketenacetalen
AU1278801A (en) Method for generating information related to the molecular structure of a biomolecule
ATE226198T1 (de) Ein verfahren zur herstellung von tetraaza makrocyclen
DE502004002431D1 (de) Verfahren zur Herstellung alkoxyreiner Erdalkalialkoxide
DE50013786D1 (de) Polyurethanharnstofffasern mit erhöhter festigkeit
ATE365192T1 (de) Verfahren zur herstellung eines modifizierten diisocyanats, verfahren zur herstellung eines selbstschmierenden emaillelackes, verfahren zur herstellung eines lackisolierten elektrischen leiters
WO2005121204A3 (en) Polyhydroxyalkanoic acid having vinyl, ester, carboxyl or sulfonic acid group and producing method therefor
ATE386027T1 (de) Verfahren zur herstellung von valsartan
DE50110561D1 (de) Non-metallocene, verfahren zur herstellung von diesen und deren verwendung zur polymerisation von olefinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties